دورية أكاديمية
أعرض في EDS

Therapeutic effects of in-vivo radiodynamic therapy (RDT) for lung cancer treatment: a combination of 15MV photons and 5-aminolevulinic acid (5-ALA).

التفاصيل البيبلوغرافية
العنوان: Therapeutic effects of in-vivo radiodynamic therapy (RDT) for lung cancer treatment: a combination of 15MV photons and 5-aminolevulinic acid (5-ALA).
المؤلفون: Yang DM; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States of America., Cvetkovic D; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States of America., Chen L; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States of America., Ma CC; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States of America.
المصدر: Biomedical physics & engineering express [Biomed Phys Eng Express] 2022 Nov 04; Vol. 8 (6). Date of Electronic Publication: 2022 Nov 04.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: IOP Publishing Ltd Country of Publication: England NLM ID: 101675002 Publication Model: Electronic Cited Medium: Internet ISSN: 2057-1976 (Electronic) Linking ISSN: 20571976 NLM ISO Abbreviation: Biomed Phys Eng Express Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Bristol : IOP Publishing Ltd., [2015]-
مواضيع طبية MeSH: Aminolevulinic Acid*/therapeutic use , Lung Neoplasms*/therapy , Lung Neoplasms*/drug therapy, Animals ; Mice ; Positron Emission Tomography Computed Tomography/methods ; Fluorodeoxyglucose F18 ; Mice, Inbred C57BL
مستخلص: Objective. Radiodynamic therapy (RDT) uses high-energy photon beams instead of visible/near-infrared light to treat deep-seated tumors that photodynamic therapy cannot achieve due to the low penetration depth of laser beams. The purpose of this study is to investigate the therapeutic effect of RDT with 15 MV photon beams combined with 5-aminolevulinic acid (5-ALA) using a mouse model. Approach. A subcutaneous C57BL/6 mouse model of KP1 small-cell lung cancer cell line was used. The tumors (N = 120) were randomized into four groups to observe individual and synergistic effects of 5-ALA and radiation treatment: control (untreated, N = 42), radiation treatment (RT) only (N = 20), 5-ALA only (N = 20), and RDT (N = 38). For the RT only and RDT groups, 4 Gy in a single fraction was delivered to the tumors using 15 MV photons. For the 5-ALA only and RDT groups, 5-ALA was injected at a dose of 100 mg kg -1 by tail-vein 4 h prior to RT. The tumor response was assessed by monitoring tumor growth using 1.5 T MR, maximum standardized uptake value (SUV max ) and total lesion glycolysis (TLG) using [ 18 F]FDG PET/CT, and animal survival. Main results. RDT achieved a statistically significant delay in tumor growth by 52.1%, 48.1%, and 57.9% 7 days post-treatment compared to 5-ALA only, RT only, and control group ( P <  0.001), respectively. There were no significant differences in tumor growth between 5-ALA only and RT only groups. An additional 38.5%-40.9% decrease in tumor growth was observed, showing a synergistic effect with RDT. Furthermore, RDT significantly decreased [ 18 F]FDG uptakes in SUV max and TLG 7 days post-treatment by 47.4% and 66.5% ( P <  0.001), respectively. RDT mice survived the longest of all treatment groups. Significance. RDT with 15 MV photons and 5-ALA resulted in greater tumor control compared to the control and other treatment groups. A significant synergistic effect was also observed with RDT. These preliminary results demonstrate an effective cancer treatment modality.
(© 2022 IOP Publishing Ltd.)
References: PeerJ. 2019 Oct 10;7:e7822. (PMID: 31616594)
Biochem J. 1960 Jun;75(3):620-3. (PMID: 16748818)
Nat Rev Cancer. 2003 May;3(5):380-7. (PMID: 12724736)
Tuberc Respir Dis (Seoul). 2020 Jan;83(1):61-70. (PMID: 31905433)
Sci Rep. 2018 Feb 9;8(1):2728. (PMID: 29426920)
Radiology. 2012 Aug;264(2):559-66. (PMID: 22692034)
Photochem Photobiol. 2002 Nov;76(5):518-25. (PMID: 12462647)
Biomedicines. 2021 Mar 22;9(3):. (PMID: 33810115)
Phys Med Biol. 2020 Aug 19;65(16):165008. (PMID: 32464613)
Oncol Lett. 2019 Jun;17(6):5132-5138. (PMID: 31186727)
Nat Commun. 2018 Oct 17;9(1):4321. (PMID: 30333489)
J Surg Oncol. 2008 May 1;97(6):523-8. (PMID: 18348188)
Int J Mol Med. 2017 Feb;39(2):387-398. (PMID: 28035368)
Int J Mol Sci. 2019 Oct 17;20(20):. (PMID: 31627442)
Int J Clin Exp Med. 2015 May 15;8(5):6829-34. (PMID: 26221221)
Prostate. 2019 Mar;79(4):340-351. (PMID: 30450646)
Mol Med Rep. 2015 Mar;11(3):1813-9. (PMID: 25420581)
Oncology. 2002;62(1):85-93. (PMID: 11810048)
Anticancer Res. 2013 May;33(5):1799-807. (PMID: 23645724)
Cancers (Basel). 2021 Feb 02;13(3):. (PMID: 33540759)
Oncol Rep. 2015 Feb;33(2):583-90. (PMID: 25420428)
Oncol Rep. 2012 Jun;27(6):1748-52. (PMID: 22378066)
Adv Drug Deliv Rev. 2001 Jul 2;49(1-2):71-86. (PMID: 11377804)
Int J Radiat Biol. 2016 Dec;92(12):774-789. (PMID: 27586078)
J Nucl Med. 2019 Jan;60(1):142-149. (PMID: 29903933)
Clin Endosc. 2021 Jul;54(4):494-498. (PMID: 32422695)
Springerplus. 2013 Nov 12;2:602. (PMID: 24324921)
Med Phys. 2011 Jul;38(7):4127-32. (PMID: 21859013)
Int J Mol Sci. 2021 Sep 09;22(18):. (PMID: 34575921)
معلومات مُعتمدة: P30 CA006927 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: 5-aminolevulinic acid (5-ALA); MRI; PET/CT; cancer treatment; radiodynamic therapy (RDT); therapeutic effect; tumor control
المشرفين على المادة: 88755TAZ87 (Aminolevulinic Acid)
0Z5B2CJX4D (Fluorodeoxyglucose F18)
تواريخ الأحداث: Date Created: 20221020 Date Completed: 20221108 Latest Revision: 20230505
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9916272
DOI: 10.1088/2057-1976/ac9b5c
PMID: 36263662
قاعدة البيانات: MEDLINE
الوصف
تدمد:2057-1976
DOI:10.1088/2057-1976/ac9b5c